The Filing Desk

Viridian Therapeutics

VRDN · Nasdaq · Health Care · Financials, fiscal 2016 to 2025

VRDN · Last close · November 13, 2026
$30.87
Value Viridian Therapeutics yourself

Viridian Therapeutics' revenue rose 23359.9% to $71 million in fiscal 2025. Its operating margin was −512.9%, up from −99,018.2% a year earlier. Free cash flow was −$277 million.

Viridian Therapeutics, Inc./DE Latest fiscal year ended December 31, 2025 10-K filed February 26, 2026 · 0001590750-26-000007 Updated
Revenue
$71M
23359.9%
Operating margin
−512.9%
98505.3 pts
Net income
−$343M
 
Free cash flow
−$277M
 
Return on equity
−49.2%
0.7 pts
Market cap
$2.5B
Nov 13 close
P/E
—
 

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

About these figures. Share counts and per-share figures for earlier years are restated for a stock split (1-for-14.9254), so every year is on today's share basis.

Charts show fiscal years, from the 10-K filings.

What Viridian Therapeutics does

Viridian Therapeutics is a biotechnology company developing antibody medicines for autoimmune and rare diseases. It has no approved product and has never had revenue from product sales. Its main focus is thyroid eye disease (TED), a rare autoimmune condition that causes inflammation around the eye and can make the eyes bulge.

Its lead candidate, veligrotug, targets a protein called IGF-1R. The company sent a marketing application for it to the FDA in October 2025. The FDA accepted it for filing in December 2025, gave it Priority Review and set a target decision date of June 30, 2026. The company is also running a global phase 3 trial called STRIVE. It has candidates that block FcRn, a protein linked to several autoimmune disorders, and an inhibitor of TSHR for TED and Graves' disease.

The company says it is preparing to launch its first product, if approved. It is building sales, marketing, patient services and supply operations. It finds drugs through its own research and by licensing them from others, and it can make biologic medicines itself.

Its biggest risks, as it describes them

  • Losses since it began and no revenue from product sales, so it may never be profitable.
  • Needing more capital, which could dilute shareholders or force it to cut back programs.
  • Clinical trials that are costly, slow and may fail to show safety and effectiveness.
  • Regulatory approval that may be delayed or refused, and ongoing rules even after approval.
  • Not being entitled to further milestone payments under the DRI Purchase and Sale Agreement.
From Viridian Therapeutics's annual report on Form 10-K, filed February 26, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

Viridian Therapeutics lost money in fiscal 2025: a net loss of $343 million.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red. Where the filings' structured data doesn't give a year's earnings per share, the column is blank.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments197425477718875
Debt incl. finance leases052021—
Net debt (negative means net cash)−197−420−457−697—
Net debt to EBITDA—————
Debt to equity0.0x0.0x0.1x0.0x—
Interest coverage−26,576.0x−268.6x−191.2x−136.1x−73.4x
Current ratio14.7x12.9x18.3x15.4x12.7x
Quick ratio14.7x12.9x18.3x15.4x12.7x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project Viridian Therapeutics' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

Insider trades

Over the 12 months between November 14, 2025 and November 13, 2026, 1 insider bought $20.0 million of Viridian Therapeutics shares on the open market, and 1 insider sold $418,990.

Buys and sells by month
US$ millions, open-market purchases (up) and sales (down) by officers, directors and 10% owners in each month.
BoughtSold
DateInsiderTradeSharesPriceValueFiling
Aug 19, 2026Jennifer TousignantChief Legal OfficerSold14,212$24.50$348,194Form 4
May 11, 2026Fairmount Healthcare Fund II L.P.Director, 10% ownerBought1,176,470$17.00$20.0 millionForm 4
Dec 31, 2025Jennifer TousignantChief Legal OfficerSold2,272$31.16$70,796Form 4
Open-market purchases and sales by officers, directors and 10% owners, from their Form 4 filings with the SEC: one row per person, day and filing, at the day's average price. Grants, option exercises and shares withheld for tax aren't counted. Insiders buy and sell for many reasons, such as taxes, spreading their savings or a plan set up months earlier, so a trade on its own says little about where a company is heading. For information only, not investment advice. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score3 of 8——
Rule of 40−59,021.1%−77,099.9%22,969.1%
Altman Z''7.438.992.72
Accruals ratio−11.6%−6.1%−8.1%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailFailFail
Cash from operations is positiveFailFailFail
Return on assets rosePassFailPass
Cash from operations exceeds net incomePassPassPass
Debt fell relative to assetsFailPass—
Current ratio rosePassFailFail
Share count didn't riseFail——
Gross margin rose———
Revenue rose relative to assetsFailFailPass
F-score3 of 8——
Companies that report no gross profit are scored on the other eight.

Compare

Put Viridian Therapeutics side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
Viridian TherapeuticsFY2523,359.9%−512.9%−390.8%———
Kura OncologyFY2525.2%−449.9%−104.8%——3Compare
Nuvation BioFY25699.0%−338.7%−288.4%———Compare
Eton PharmaceuticalsFY25104.9%−1.1%12.8%−1.9%1.4x4Compare
Tango TherapeuticsFY2548.3%−178.4%−224.3%———Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

10 years of figures

Fiscal yearFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue44841320071
Revenue growth−39.1%15.1%109.5%−46.8%−76.5%182.2%−40.2%−82.3%−3.8%23,359.9%
Gross profit1—————————
Research and development142030352857101160238339
Operating income−17−26−33−42−110−80−134−254−299−363
Net income−17−26−33−42−111−79−130−238−270−343
Diluted EPS (US$)−423.15−20.70−16.50−20.04−31.13−6.66−4.05−5.31——
Diluted shares (millions)01224123245——
Cash flow
Cash from operations−15−28−27−36−30−55−94−184−232−276
Capital expenditure0000001100
Free cash flow−15−28−27−36−30−55−95−185−233−277
Dividends paid0000000000
Share buybacks0000000000
Acquisitions0000000000
Stock-based compensation024441420674244
Balance sheet at fiscal year end
Cash and short-term investments22476227128197425477718875
Debt incl. finance leases5101080052021—
Total assets25526630131204435490742899
Total liabilities101415141116404871177
Shareholders' equity−62385116120188395442672722
Margins and ratios
Gross margin26.7%—————————
Operating margin−488.6%−662.8%−394.5%−941.0%−10,512.4%−2,690.8%−7,579.2%−81,035.0%−99,018.2%−512.9%
Net margin−496.8%−662.3%−390.0%−938.6%−10,544.3%−2,680.2%−7,329.2%−75,711.5%−89,387.1%−483.6%
Free cash flow margin−431.6%−709.8%−325.4%−810.1%−2,840.1%−1,853.5%−5,340.6%−58,938.8%−77,096.0%−390.8%
Rule of 40 (growth + FCF margin)−470.6%−694.7%−215.9%−856.9%−2,916.6%−1,671.3%−5,380.8%−59,021.1%−77,099.9%22,969.1%
Return on capital——————————
Return on equity——−72.8%−124.8%−163.1%−51.6%−44.6%−56.8%−48.5%−49.2%
Return on assets−91.7%−68.7%−55.1%−86.9%−137.1%−47.4%−40.7%−51.4%−43.8%−41.7%
Net debt to EBITDA——————————
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Viridian Therapeutics' Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Viridian Therapeutics.